ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.
News
Cambridge, UK, 17 August 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today announces its unaudited results for the six months ended 30 June 2020.
Group Financial Highlights
Westbury, NY – Aug. 14, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is now offering same- or next-day delivery of fresh blood and immune cell products from its seven blood donor centers, which are strategically located near biopharma hubs in the US and UK, to almost anywhere in the world.
While pharmaceuticals contribute to approximately 2% of annual air cargo volume, the industry transports over one trillion dollars’ worth of cargo every year (IATA). Pharmaceutical shipments have an overwhelmingly large impact on the global response to infectious diseases and general healthcare.
COVID-19 has shown that effective healthcare logistics management requires not only regulatory expertise and extensive planning, but also a proactive global network of logistics experts who can respond to last-minute changes, namely flight cancellations and lockdowns.
- CRISPR-based screening technology platform to address critical gaps in target ID and validation
- Single cell RNAseq-linked pooled CRISPR screening offers high-quality screening data and biological insight
Chesterford Research Park management team and Diagnostics for the Real World work together, re-purposing space to create efficient assembly line
£2.5m of Government funding to accelerate delivery of Incubator at Discovery Park
Science Park helping to drive local economic growth with SELEP support
Situation:
The coronavirus (COVID-19) pandemic has presented an enormous challenge to individuals and organisations worldwide. Adapting to living with the threat of the SARS-CoV-2 virus among our communities has required significant changes in how we behave and operate.
Our position:
Where next for UK life sciences regulation?, Where next for the EU’s pharmaceutical strategy? International data transfers after the demise of the US Privacy Shield, Supply chain resilience, and much more…..
Sequence - July 2020 - Issue 11
- AlmirallShare launches its fifth call for proposals, aiming to establish partnerships to find new assets—new chemical entities, biologics and other advanced therapies—for the treatment of dermatological conditions
- Scientists can participate until October 31, 2020
- AlmirallShare is responsible for 50% of the private-public collaborations at Almirall. This open innovation platform has received more than 350 proposals since its launch in 2017